In the twenty-first century, identifying the molecular subsets of lung adenocarcinoma characterized by specific oncogenic drivers (e.g., epidermal growth factor receptor [EGFR]) has led to remarkable improvements in the treatments and outcomes for various lung cancers with tyrosine kinase inhibitors (TKI) [5]. This evidence concerns the gene EGFR and lung adenocarcinoma.